Scott Bizily - 08 Feb 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal Officer
Signature
By: /s/ Scott Bizily
Issuer symbol
FDMT
Transactions as of
08 Feb 2024
Net transactions value
-$108,124
Form type
4
Filing time
12 Feb 2024, 21:04:28 UTC
Previous filing
13 Dec 2023
Next filing
21 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $8,645 +1,332 +77% $6.49 3,069 08 Feb 2024 Direct F1
transaction FDMT Common Stock Sale $36,630 -1,332 -43% $27.50 1,737 08 Feb 2024 Direct F1
transaction FDMT Common Stock Options Exercise $23,445 +2,916 +168% $8.04 4,653 08 Feb 2024 Direct F1
transaction FDMT Common Stock Sale $80,190 -2,916 -63% $27.50 1,737 08 Feb 2024 Direct F1
transaction FDMT Common Stock Options Exercise $31,497 +1,996 +115% $15.78 3,733 08 Feb 2024 Direct F1
transaction FDMT Common Stock Sale $54,890 -1,996 -53% $27.50 1,737 08 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -1,332 -7.2% $0.000000 17,043 08 Feb 2024 Common Stock 1,332 $6.49 Direct F1, F2
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -2,916 -6% $0.000000 45,834 08 Feb 2024 Common Stock 2,916 $8.04 Direct F1, F3
transaction FDMT Stock Option (Right to Buy) Options Exercise $0 -1,996 -8% $0.000000 23,004 08 Feb 2024 Common Stock 1,996 $15.78 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F3 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
F4 The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.